The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy

Area of Science:

• Oncology
• Immunotherapy
• Cancer Genetics

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is a significant advancement for treating refractory hematologic malignancies like leukemia, lymphoma, and myeloma.
• Recent FDA investigations have highlighted concerns regarding second primary malignancies (SPM) following CAR T-cell therapy.

Purpose of the Study:

• To review the potential mechanisms by which CAR T-cells may transform into CAR+ SPM.
• To explore the genetic and molecular pathways involved in T-cell lymphomagenesis post-CAR T-cell treatment.

Main Methods:

• Literature review of genetic and molecular pathways.
• Analysis of the balance between CAR T-cell persistence, stemness, and oncogenic risk.
• Examination of the role of T-cell exhaustion in mitigating lymphomagenesis.

Main Results:

• Genetically modified T cells may undergo transformation into CAR+ SPM through various genetic and molecular pathways.
• The persistence and stemness of CAR T-cells are linked to oncogenic risk.
• T-cell exhaustion may reduce therapy efficacy but potentially lower the risk of lymphomagenesis.

Conclusions:

• The origin of SPM post-CAR T-cell therapy requires further investigation, with potential links to pre-existing or therapy-induced genetic alterations.
• Technological advancements, robust regulatory oversight, and diligent patient monitoring are essential to mitigate the risks associated with CAR T-cell therapy.